Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06773403 · ClinicalTrials.gov registry record · Phase 4
Upadacitinib for Prurigo Nodularis
A Phase 4 study of Prurigo Nodularis, sponsored by Psoriasis Treatment Center of Central New Jersey.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT06773403: Recruiting Phase 4 study of Prurigo Nodularis, sponsored by Psoriasis Treatment Center of Central New Jersey.
NCT06773403 is a Phase 4 study of Prurigo Nodularis that is actively recruiting participants, run by Psoriasis Treatment Center of Central New Jersey. The registered enrollment target is 25 participants, below the 228-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06773403, a Phase 4 study of Prurigo Nodularis, is actively recruiting participants, sponsored by Psoriasis Treatment Center of Central New Jersey.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
A single center, open-label study of 25 subjects to assess 24 weeks upadacitinib in patients with moderate-to-severe prurigo nodularis.
Primary Outcome
Proportion of participants with improvement (change) in worst-itch numeric rating scale (WI-NRS) by ≥4 points from baseline to Week 12.
Conditions Studied
Interventions
- DRUG Upadacitinib
Study Locations (1)
New Jersey
- Eczema Treatment Center of New Jersey - East Windsor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-04-09 |
| Est. Completion | 2026-01 |
| Phase | Phase 4 |
What NCT06773403 shows while recruiting
NCT06773403 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 228-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Prurigo Nodularis appearing as the primary indexed condition, and to 1 intervention - of which Upadacitinib is the first listed.
NCT06773403 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT06773403 about?
NCT06773403 is a clinical study titled "Upadacitinib for Prurigo Nodularis". A single center, open-label study of 25 subjects to assess 24 weeks upadacitinib in patients with moderate-to-severe prurigo nodularis.
What is the current status of trial NCT06773403?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2024-04-09. Estimated completion is 2026-01.
What conditions does trial NCT06773403 study?
This clinical trial studies the following conditions: Prurigo Nodularis.
What interventions are being tested in trial NCT06773403?
The interventions under investigation include: Upadacitinib (DRUG).
Who is sponsoring clinical trial NCT06773403?
This trial is sponsored by Psoriasis Treatment Center of Central New Jersey, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06773403 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prurigo Nodularis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06773403's enrollment target sits among peer trials
25 12th of 14 higher than 3 of 14 other Prurigo Nodularis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prurigo Nodularis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
RECRUITING · Phase 3
-
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
RECRUITING · Phase 3
-
Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
RECRUITING
-
Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
ACTIVE NOT RECRUITING
-
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI